ELDN - Company ID 0001404281
The table below shows Eledon Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $66.27M | $51.96M | $30.31M | $27.08M | $23.73M | $6.13M |
| SG&A | $16.98M |
Eledon Pharmaceuticals, Inc. reported annual revenue of $0.00 for fiscal year 2016. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $18.61M |
| $12.69M |
| $12.70M |
| $13.13M |
| $10.05M |
| Operating income | - | - | -$43.00M | -$88.43M | -$36.87M | -$18.46M |
| Income tax | $35.00K | $431.00K | $0.00 | $0.00 | -$2.35M | -$404.00K |
| Net income | -$45.62M | -$36.18M | -$116.54M | -$87.97M | -$34.51M | -$22.81M |
| EPS (diluted) | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | - |